Derm News: 2007.24(9)

Lichen planus responding to efalizumab

Journal of the American Academy of Dermatology, 56(5 Suppl):S92-S93
Markus Böhm, Thomas A. Luger
ABSTRACT

Lichen planus (LP) is a common inflammatory skin disorder of unknown origin. When generalized and relapsing, treatment of LP can be a challenge. We present a patient with widespread and relapsing generalized LP who was treated with efalizumab for 3 months. Both pruritus and the skin lesions responded promptly to this biologic. In accordance with the previously reported efficacy in oral erosive LP, efalizumab may be a promising novel future treatment option for patients with cutaneous LP.

    Back to Current Volume:   Dermatology News 2007.24

The Derm News service provided by the Editorial Consultants of Skin Therapy Letter^© and its founding editor Dr. Stuart Maddin.